Correction to: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases (PLOS Medicine, (2016), 13, 12, (e1002174), 10.1371/journal.pmed.1002174);Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases

PLoS Medicine

Volumn 13, Issue 12, 2016, Pages

  Hoadley, Katherine A ^a,b   Siegel, Marni B ^a,b   Kanchi, Krishna L ^c   Miller, Christopher A ^c   Ding, Li ^c   Zhao, Wei ^a,b   He, Xiaping ^b   Parker, Joel S ^a,b   Wendl, Michael C ^c,d   Fulton, Robert S ^c   Demeter, Ryan T ^c   Wilson, Richard K ^c   Carey, Lisa A ^a   Perou, Charles M ^a,b   Mardis, Elaine R ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; MESSENGER RNA; PACLITAXEL; PROTEIN P53;

ADULT; AGED; ARTICLE; AUTOPSY; BASAL LIKE BREAST CANCER; CANCER RADIOTHERAPY; CASE REPORT; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; HUMAN TISSUE; MASTECTOMY; METASTASIS POTENTIAL; MIDDLE AGED; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; RETROSPECTIVE STUDY; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; BASAL CELL CARCINOMA; BREAST TUMOR; DISEASE COURSE; GENETICS; MUTATION; SECONDARY;

AGED; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENOMICS; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, BASAL CELL; RETROSPECTIVE STUDIES;

EID: 85007559199     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002222     Document Type: Erratum

References (57)

1. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;132: 523–35. doi: 10.1007/s10549-011-1619-721671017
2. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res BCR. 2011;13: R87. doi: 10.1186/bcr294421914172
3. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68: 3108–3114. doi: 10.1158/0008-5472.CAN-07-564418451135
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366: 883–892. doi: 10.1056/NEJMoa111320522397650
5. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346: 256–259. doi: 10.1126/science.125693025301631
6. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346: 251–256. doi: 10.1126/science.125346225301630
7. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520: 353–357. doi: 10.1038/nature1434725830880
8. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis. PLOS Med. 2015;12: e1001789. doi: 10.1371/journal.pmed.100178925710373
9. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5: 1164–1177. doi: 10.1158/2159-8290.CD-15-036926410082
10. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014;13: 1382–1389. doi: 10.1158/1535-7163.MCT-13-048224608573
11. Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232: 23–31. doi: 10.1002/path.428824122263
12. Moelans CB, van der Groep P, Hoefnagel LDC, van de Vijver MJ, Wesseling P, Wesseling J, et al. Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Lett. 2014;344: 138–146. doi: 10.1016/j.canlet.2013.10.02524184827
13. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015;373: 1926–1936. doi: 10.1056/NEJMoa150258326559571
14. McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, et al. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nat Med. 2015;21: 1514–1520. doi: 10.1038/nm.397926523969
15. Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM, Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. BMC Genomics. 2014;15: 419. doi: 10.1186/1471-2164-15-41924888378
16. Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 2010;38: e178. doi: 10.1093/nar/gkq62220802226
17. Li B, Dewey CN, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12: 323. doi: 10.1186/1471-2105-12-32321816040
18. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015;163: 506–519. doi: 10.1016/j.cell.2015.09.03326451490
19. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27: 1160–1167. doi: 10.1200/JCO.2008.18.137019204204
20. de Hoon MJL, Imoto S, Nolan J, Miyano S, Open source clustering software. Bioinformatics. 2004;20: 1453–1454. doi: 10.1093/bioinformatics/bth07814871861
21. Saldanha AJ, Java Treeview—extensible visualization of microarray data. Bioinformatics. 2004;20: 3246–3248. doi: 10.1093/bioinformatics/bth34915180930
22. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361: 1058–1066. doi: 10.1056/NEJMoa090384019657110
23. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150: 1121–1134. doi: 10.1016/j.cell.2012.08.02422980976
24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinforma Oxf Engl. 2009;25: 2078–2079. doi: 10.1093/bioinformatics/btp35219505943
25. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinforma Oxf Engl. 2012;28: 311–317. doi: 10.1093/bioinformatics/btr66522155872
26. Larson DE, Abbott TE, Wilson RK, Using SomaticSniper to Detect Somatic Single Nucleotide Variants. Curr Protoc Bioinforma Ed Board Andreas Baxevanis Al. 2014;15: 1–8. doi: 10.1002/0471250953.bi1505s4525431635
27. Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456: 66–72. doi: 10.1038/nature0748518987736
28. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29: 308–311. 11125122
29. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z, Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinforma Oxf Engl. 2009;25: 2865–2871. doi: 10.1093/bioinformatics/btp39419561018
30. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20: 1297–1303. doi: 10.1101/gr.107524.11020644199
31. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22: 568–576. doi: 10.1101/gr.129684.11122300766
32. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods. 2009;6: 677–681. doi: 10.1038/nmeth.136319668202
33. Chen K, Chen L, Fan X, Wallis J, Ding L, Weinstock G, TIGRA: a targeted iterative graph routing assembler for breakpoint assembly. Genome Res. 2014;24: 310–317. doi: 10.1101/gr.162883.11324307552
34. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43: 491–498. doi: 10.1038/ng.80621478889
35. Thorvaldsdóttir H, Robinson JT, Mesirov JP, Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013;14: 178–192. doi: 10.1093/bib/bbs01722517427
36. Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 2014;42: e107. doi: 10.1093/nar/gku48924970867
37. Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol. 2014;10: e1003665. doi: 10.1371/journal.pcbi.100366525102416
38. Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget. 2016; doi: 10.18632/oncotarget.834927028851
39. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43: D805–D811. doi: 10.1093/nar/gku107525355519
40. Cancer Genome Atlas N, Comprehensive molecular portraits of human breast tumours. Nature. 2012;490: 61–70. doi: 10.1038/nature1141223000897
41. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2: 401–404. doi: 10.1158/2159-8290.CD-12-009522588877
42. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6: pl1. doi: 10.1126/scisignal.200408823550210
43. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486: 395–399. doi: 10.1038/nature1093322495314
44. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D, GeneCards: integrating information about genes, proteins and diseases. Trends Genet TIG. 1997;13: 163. 9097728
45. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464: 999–1005. doi: 10.1038/nature0898920393555
46. Ip LRH, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, et al. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget. 2015;6: 10548–10562. doi: 10.18632/oncotarget.330725868852
47. Weigman VJ, Chao H-H, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133: 865–880. doi: 10.1007/s10549-011-1846-y22048815
48. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009;16: 115–125. doi: 10.1016/j.ccr.2009.06.00619647222
49. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A. 2008;105: 13081–13086. doi: 10.1073/pnas.080152310518723673
50. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472: 90–94. doi: 10.1038/nature0980721399628
51. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21: 751–759. doi: 10.1038/nm.388626099045
52. Anders C, Carey LA, Understanding and treating triple-negative breast cancer. Oncol Williston Park. 2008;22: 1233–1239. 18980022
53. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Rep. 2013;4. doi: 10.1016/j.celrep.2013.08.02224055055
54. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2015;518: 240–244. doi: 10.1038/nature1394825409150
55. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun. 2016;7: 12498. doi: 10.1038/ncomms1249827502118
56. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. Cancer Epidemiol Biomarkers Prev. 2012;21: 1848–1855. doi: 10.1158/1055-9965.EPI-12-047422989461
57. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486: 353–360. doi: 10.1038/nature1114322722193